Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 743,293
  • Shares Outstanding, K 99,238
  • Annual Sales, $ 63,530 K
  • Annual Income, $ -160,930 K
  • 60-Month Beta 1.67
  • Price/Sales 11.29
  • Price/Cash Flow N/A
  • Price/Book 1.93
Trade FATE with:

Options Overview Details

View History
  • Implied Volatility 109.47% ( +7.06%)
  • Historical Volatility 95.24%
  • IV Percentile 72%
  • IV Rank 18.74%
  • IV High 506.59% on 10/20/23
  • IV Low 17.87% on 11/15/23
  • Put/Call Vol Ratio 0.08
  • Today's Volume 116
  • Volume Avg (30-Day) 216
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 2,289
  • Open Int (30-Day) 3,450

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.49
  • Number of Estimates 9
  • High Estimate -0.45
  • Low Estimate -0.56
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -157.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.47 +8.89%
on 02/21/24
8.83 -20.27%
on 03/07/24
-0.52 (-6.88%)
since 02/16/24
3-Month
3.05 +130.82%
on 12/20/23
8.83 -20.27%
on 03/07/24
+3.89 (+123.49%)
since 12/18/23
52-Week
1.63 +331.90%
on 10/30/23
8.83 -20.27%
on 03/07/24
+1.50 (+27.08%)
since 03/17/23

Most Recent Stories

More News
5 Russell 2000 Stocks Outperforming the 'Magnificent Seven' in 2024

The "Magnificent Seven" have lost some momentum in 2024, just as small-caps are starting to come on strong. Here's a closer look at five Russell 2000 stocks that are crushing the performance of their mega-cap...

GOOGL : 147.68 (+4.60%)
AMZN : 174.48 (+0.03%)
AAPL : 173.72 (+0.64%)
META : 496.98 (+2.66%)
MSFT : 417.32 (+0.22%)
NVDA : 884.55 (+0.70%)
TSLA : 173.80 (+6.25%)
MAGS : 38.77 (+1.87%)
$IUXX : 17,985.01 (+0.99%)
VKTX : 63.35 (+1.26%)
SOUN : 8.24 (-7.52%)
APGE : 65.44 (-4.20%)
Fate Therapeutics: Q4 Earnings Snapshot

Fate Therapeutics: Q4 Earnings Snapshot

FATE : 7.04 (-6.01%)
Fate Therapeutics: Q3 Earnings Snapshot

Fate Therapeutics: Q3 Earnings Snapshot

FATE : 7.04 (-6.01%)
Fate Therapeutics: Q2 Earnings Snapshot

Fate Therapeutics: Q2 Earnings Snapshot

FATE : 7.04 (-6.01%)
Why Shares of Fate Therapeutics Soared This Week

The company's shares bounced back after a stock sale last week.

JNJ : 156.76 (-0.90%)
OPHLY : 5.5900 (+0.36%)
FATE : 7.04 (-6.01%)
MFG : 4.00 (+1.27%)
Bausch Health's (BHC) Q1 Earnings & Sales Miss, Shares Down

Bausch (BHC) declines as it misses on earnings and sales in the first quarter.

LGND : 72.14 (+1.48%)
FATE : 7.04 (-6.01%)
SPRO : 1.7300 (-3.35%)
BHC : 9.38 (+1.96%)
FATE Incurs Narrower-Than-Expected Q1 Loss on Lower Expenses

FATE reports lower-than-expected loss on higher collaboration revenues and lower operating expenses in first-quarter 2023.

JNJ : 156.76 (-0.90%)
LGND : 72.14 (+1.48%)
FATE : 7.04 (-6.01%)
SPRO : 1.7300 (-3.35%)
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 65.45% and 39.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

FATE : 7.04 (-6.01%)
PSTX : 3.06 (-4.97%)
Fate Therapeutics: Q1 Earnings Snapshot

Fate Therapeutics: Q1 Earnings Snapshot

FATE : 7.04 (-6.01%)
Pacira (PCRX) Q1 Earnings Miss Estimates, Revenues Beat

Pacira (PCRX) misses on Q1 earnings but beats on revenues, even though volume growth of Exparel is offset by lower selling prices.

LGND : 72.14 (+1.48%)
PCRX : 29.29 (-0.41%)
FATE : 7.04 (-6.01%)
SPRO : 1.7300 (-3.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.' The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the...

See More

Key Turning Points

3rd Resistance Point 7.93
2nd Resistance Point 7.71
1st Resistance Point 7.38
Last Price 7.04
1st Support Level 6.83
2nd Support Level 6.61
3rd Support Level 6.28

See More

52-Week High 8.83
Last Price 7.04
Fibonacci 61.8% 6.08
Fibonacci 50% 5.23
Fibonacci 38.2% 4.38
52-Week Low 1.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar